GRI Bio (GRI) Competitors $0.74 -0.03 (-3.90%) (As of 12/20/2024 05:51 PM ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestTrends GRI vs. LGVN, LPCN, NAII, LVTX, PLUR, ENLV, LSB, EQ, AKTX, and CMMBShould you be buying GRI Bio stock or one of its competitors? The main competitors of GRI Bio include Longeveron (LGVN), Lipocine (LPCN), Natural Alternatives International (NAII), LAVA Therapeutics (LVTX), Pluri (PLUR), Enlivex Therapeutics (ENLV), Lakeshore Biopharma (LSB), Equillium (EQ), Akari Therapeutics (AKTX), and Chemomab Therapeutics (CMMB). These companies are all part of the "pharmaceutical products" industry. GRI Bio vs. Longeveron Lipocine Natural Alternatives International LAVA Therapeutics Pluri Enlivex Therapeutics Lakeshore Biopharma Equillium Akari Therapeutics Chemomab Therapeutics Longeveron (NASDAQ:LGVN) and GRI Bio (NASDAQ:GRI) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their valuation, earnings, dividends, community ranking, media sentiment, profitability, risk, institutional ownership and analyst recommendations. Do insiders & institutionals have more ownership in LGVN or GRI? 10.0% of Longeveron shares are held by institutional investors. Comparatively, 34.0% of GRI Bio shares are held by institutional investors. 19.1% of Longeveron shares are held by insiders. Comparatively, 0.3% of GRI Bio shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term. Does the media prefer LGVN or GRI? In the previous week, Longeveron had 1 more articles in the media than GRI Bio. MarketBeat recorded 1 mentions for Longeveron and 0 mentions for GRI Bio. Longeveron's average media sentiment score of 0.99 beat GRI Bio's score of 0.00 indicating that Longeveron is being referred to more favorably in the media. Company Overall Sentiment Longeveron Positive GRI Bio Neutral Does the MarketBeat Community favor LGVN or GRI? Longeveron received 13 more outperform votes than GRI Bio when rated by MarketBeat users. However, 100.00% of users gave GRI Bio an outperform vote while only 94.12% of users gave Longeveron an outperform vote. CompanyUnderperformOutperformLongeveronOutperform Votes1694.12% Underperform Votes15.88%GRI BioOutperform Votes3100.00% Underperform VotesNo Votes Which has stronger valuation & earnings, LGVN or GRI? GRI Bio has lower revenue, but higher earnings than Longeveron. GRI Bio is trading at a lower price-to-earnings ratio than Longeveron, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioLongeveron$1.89M12.93-$21.41M-$6.28-0.26GRI BioN/AN/A-$13.04M-$0.93-0.80 Do analysts prefer LGVN or GRI? Longeveron currently has a consensus target price of $8.67, indicating a potential upside of 425.25%. GRI Bio has a consensus target price of $11.50, indicating a potential upside of 1,454.05%. Given GRI Bio's higher probable upside, analysts plainly believe GRI Bio is more favorable than Longeveron.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Longeveron 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 1 Strong Buy rating(s) 3.25GRI Bio 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00 Is LGVN or GRI more profitable? GRI Bio has a net margin of 0.00% compared to Longeveron's net margin of -967.49%. Longeveron's return on equity of -142.43% beat GRI Bio's return on equity.Company Net Margins Return on Equity Return on Assets Longeveron-967.49% -142.43% -100.84% GRI Bio N/A -289.05%-165.01% Which has more volatility & risk, LGVN or GRI? Longeveron has a beta of 0.31, indicating that its stock price is 69% less volatile than the S&P 500. Comparatively, GRI Bio has a beta of -2.04, indicating that its stock price is 304% less volatile than the S&P 500. SummaryLongeveron beats GRI Bio on 12 of the 18 factors compared between the two stocks. Ad Crypto 101 MediaThe #1 Coin for November 2024Grayscale Investments just announced a new fund offering access to a HOT new DeFi coin… And thanks to this newly established trust, I believe this coin could skyrocket up to 150x+ in the next 30 days alone! I've compiled everything you need to know about this once-in-a-lifetime DeFi project into a brand-new comprehensive guide… You can get access to the report by clicking here now… Get GRI Bio News Delivered to You Automatically Sign up to receive the latest news and ratings for GRI and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart GRI vs. The Competition Export to ExcelMetricGRI BioPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$6.61M$6.57B$5.14B$9.08BDividend YieldN/A3.00%5.09%4.23%P/E Ratio-0.8010.5989.9717.17Price / SalesN/A196.061,117.23117.03Price / CashN/A57.1643.0437.86Price / Book0.145.094.784.78Net Income-$13.04M$151.83M$120.31M$225.60M7 Day Performance-7.50%-2.13%-1.92%-1.23%1 Month Performance7.40%-4.55%13.64%0.46%1 Year Performance-97.54%8.87%28.32%15.25% GRI Bio Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)GRIGRI Bio2.5218 of 5 stars$0.74-3.9%$11.50+1,454.1%-97.8%$6.61MN/A-0.801LGVNLongeveron3.4375 of 5 stars$1.83-1.6%$8.67+373.6%-86.8%$27.15M$1.89M-0.3023LPCNLipocine1.5291 of 5 stars$4.97-1.0%$10.00+101.2%+66.5%$26.58M$7.92M-6.6110News CoverageNAIINatural Alternatives InternationalN/A$4.21-2.1%N/A-35.9%$26.10M$112.98M-2.99290Analyst ForecastLVTXLAVA Therapeutics3.0636 of 5 stars$1.02-8.2%$4.67+358.0%-31.8%$25.83M$7.35M-1.0860Analyst ForecastGap DownPLURPluri0.4243 of 5 stars$4.62-2.1%N/A+5.9%$25.69M$330,000.000.00150News CoverageENLVEnlivex Therapeutics2.321 of 5 stars$1.18-1.7%$9.50+705.1%-45.6%$25.26MN/A0.0070LSBLakeshore Biopharma0.4967 of 5 stars$2.65+6.4%N/AN/A$24.67M$80.82M0.00773News CoverageGap UpEQEquillium2.9048 of 5 stars$0.68-3.5%$5.00+635.3%-7.7%$24.09M$45.91M-5.0440Gap DownAKTXAkari TherapeuticsN/A$0.97-0.3%N/A-68.2%$24.02MN/A0.009Analyst ForecastGap DownCMMBChemomab Therapeutics3.3163 of 5 stars$1.65+4.4%$7.33+344.4%+242.9%$23.69MN/A-1.5820Positive News Related Companies and Tools Related Companies LGVN Alternatives LPCN Alternatives NAII Alternatives LVTX Alternatives PLUR Alternatives ENLV Alternatives LSB Alternatives EQ Alternatives AKTX Alternatives CMMB Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:GRI) was last updated on 12/22/2024 by MarketBeat.com Staff From Our Partners$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowIt’s here. This is the moment we’ve been waiting for. The next 3-6 months in crypto will be absolutely life...Crypto Swap Profits | SponsoredDid You See Trump’s Bombshell Exec. Order 001?Starting with what I call Exec. Order 001. It’s a bombshell law that I believe Trump will sign within minut...Banyan Hill Publishing | SponsoredCould This Tiny Device Help You Make an Extra $30k a Year?I believe it’s going to power Elon Musk’s next AI revolution… A revolution he believes will be worth more t...Brownstone Research | SponsoredHOTTEST TRADER IN AMERICA 🔥🔥🔥Ready for a rocket ride this weekend? After alerting his readers to a tiny $2 stock called Bright Minds Bio...Timothy Sykes | SponsoredBuffett's Oil Bet + This 22% Dividend PlayWarren Buffett has been quietly amassing a massive position in oil stocks. But while Buffett's picks (Occid...Investors Alley | SponsoredBuy this coin BEFORE Inauguration Day …Mark my words … Bitcoin is going to $100,000. BEFORE Trump is inaugurated. And I think it could reach $1...Weiss Ratings | SponsoredPlease don’t take this warning lightly…Something huge is about to hit the stock market. Wall St. legend Louis Navellier calls it: "The most signif...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding GRI Bio, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share GRI Bio With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free GRI Stock Alerts